Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94103


This study will evaluate a test designed to measure immune system responses to HIV and HIV vaccines.

Study summary:

Assays for HIV-specific human CD4 and CD8 T cell immunity are needed in order to evaluate the immune response to HIV vaccines. Such assays should be robust, reproducible, and amenable to high throughput analysis of clinical specimens. Cytokine flow cytometry (CFC) assays can reliably and specifically detect human CD4 and CD8 T cell responses to AIDS-related opportunistic infections, including those caused by cytomegalovirus, Mycobacterium tuberculosis, the Mycobacterium avium complex, cryptococcus, and human papillomavirus. The purpose of this study is to devise and evaluate a similar CFC assay for the detection and quantitation of CD4 and CD8 T cell responses against HIV. This study will evaluate a "Gag-IFNg CFC" assay by comparing the results of this assay with results from other assays of immune phenotype and function in long-term nonprogressors, untreated patients with progressive HIV disease, and recipients of candidate HIV vaccines. The study will also examine HIV-specific immune responses in HIV infected individuals who appear to exhibit significant immune protection from HIV disease. Participants in this study will be drawn from other studies currently underway. As a part of those studies, participants will have regular blood tests. Blood samples from those studies will be used in this study. No participants will be directly enrolled in this study.


Blood samples from 5 cohorts of HIV infected individuals and 2 cohorts of HIV uninfected individuals will be evaluated. Varying stages of HIV disease are represented in these cohorts, including: - Individuals who have been exposed but who have not seroconverted - Individuals who have recently seroconverted - HAART-treated patients who receive immune modulators such as IL-2 and therapeutic immunization - HAART-treated patients who undergo structured treatment interruptions - HAART-treated patients who have durable suppression of viremia - HAART-treated patients who experience incomplete suppression of viremia - HAART-treated patients followed with careful drug adherence monitoring - Long-term nonprogressors - Untreated progressors



Primary Contact:

Principal Investigator
Joseph M. McCune, MD, PhD
University of California at San Francisco

Backup Contact:


Location Contact:

San Francisco, California 94103
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.